Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Amniocentesis Stories

2014-04-02 16:31:06

MARIETTA, Ga., April 2, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the first quarter ended March 31, 2014, will be released before the opening of the market on Friday, April 25, 2014. MiMedx will host a live broadcast of its first quarter conference call on Friday, April 25, 2014 at 10:30am EDT....

2014-03-28 16:22:35

MARIETTA, Ga., March 28, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 13(th) Annual Needham Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present...

2014-03-19 04:21:22

DUBLIN, March 19, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/tdmwb8/noninvasive) has announced the addition of the "Non-Invasive Prenatal Testing (NIPT) Market Report" [http://www.researchandmarkets.com/research/tdmwb8/noninvasive ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Non-invasive prenatal testing is increasingly being adopted by high risk pregnant women for the...

2014-03-17 12:27:33

MARIETTA, Ga., March 17, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2(nd) Annual Regen Med Investor Day in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on...

2014-02-25 20:21:43

THE JOURNAL ENTITLED "NATURE REVIEWS RHEUMATOLOGY" HIGHLIGHTS THIS PUBLICATION MARIETTA, Ga., Feb. 25, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today a MiMedx-sponsored study from Georgia Institute of Technology has been published in Arthritis Research & Therapy. The article, titled "Intra-articular...

2014-02-07 16:24:32

MARIETTA, Ga., Feb. 7, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, today issued the following statement regarding a blog post published today on Seeking Alpha. Shareholders should not rely on Seeking Alpha type articles regardless of whether they are positive or negative. The primary source of information should be the Company's...

2014-01-13 12:28:02

MARIETTA, Ga., Jan. 13, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced the schedule for its presentation at the 32(nd) Annual J.P. Morgan Healthcare Conference. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, will present on Thursday,...

2014-01-10 08:24:03

FORT LAUDERDALE, Fla., Jan. 10, 2014 /PRNewswire/ -- Lubell Rosen partners Mark L. Rosen and Steve L. Lubell announced Wednesday the successful appellate judgment for their client, defendants OB/GYN Specialists of the Palm Beaches and Marie Morel, M.D. Lubell & Rosen and West Palm Beach appellate attorneys Rebecca Mercier Vargas and Jane Kreusler-Walsh of Kreusler-Walsh, Compiani & Vargas appealed a final judgment awarding the plaintiffs $2.5 million in damages, following a...

2013-11-19 12:30:05

Follow Up Study Accepted For Publication In Wound Medicine MARIETTA, Ga., Nov. 19, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "Dehydrated Human Amnion/Chorion Membrane Allografts in Patients with Chronic Diabetic Foot Ulcers: A Long-term Follow-up Study" has been accepted for publication...

2013-11-04 16:08:36

Summary Parents who conceive through assisted reproductive technologies (ART) are likely to receive different medical advice in relation to prenatal testing than those who conceive naturally, academics have suggested. Further detail An international study has revealed that almost 45% of clinicians would recommend a 37-year-old mother undergo amniocentesis – an invasive test which screens for Down’s syndrome – if she had conceived naturally. However, just 19% of doctors would...